FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965486534> ?p ?o ?g. }

• W1965486534 endingPage "405" @default.
• W1965486534 startingPage "396" @default.
• W1965486534 abstract "Recent trials and extensive postmarketing use confirm the efficacy and safety of oxcarbazepine (OXC) as a first-line treatment for adults and children with simple partial seizures, complex partial seizures, and partial seizures evolving to secondarily generalized seizures. OXC undergoes reductive metabolism at its keto moiety to form 10-hydroxy-10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide (MHD), which is glucuronidated and excreted in the urine, with minimal involvement of the hepatic cytochrome P450-dependent enzymes. OXC has some drug interactions, and does not require titration, allowing for better tolerability. Titration for monotherapy and adjunctive therapy of OXC could begin at 150 mg/day and be increased by 150 mg every 2-3 days until the target dose of 900-1200 mg/day is reached. If necessary, one can go faster and start with up to 600 mg/day and titrate with weekly increments up to 600 mg/day if necessary for seizure control. Conversion to monotherapy can be done overnight or gradually. For gradual conversion, use the recommended titration of OXC and withdraw the baseline antiepileptic drugs gradually by 25%, starting at Day 14 or earlier in case of baseline tolerability issues. Consider reducing the dose of the primary antiepileptic drug during adjunctive therapy in case of adverse events or increase the dose of OXC in case of incomplete seizure control. In children OXC should be started at 8-10 mg/kg/day in two or three divided doses. If clinically indicated the dose can then be increased by 10 mg/kg/day in weekly intervals with final doses up to 30-46 mg/kg/day. Dose adjustment may be necessary in very young children (age 2-5 years) and in patients with renal dysfunction, based on renal clearance. However no adjustment of OXC dose is needed in patients with mild to moderate hepatic dysfunction. OXC has a number of advantages which include rapid titration, no need for safety monitoring (except for uncommon and mostly asymptomatic hyponatremia), a low potential for drug-drug interactions (except for those possibly impairing the effectiveness of oral contraceptives and increasing the serum concentration of phenytoin), a rash rate of less than 5%, similar efficacy and similar or better tolerability and safety compared with first-generation antiepileptic drugs. OXC is a valuable alternative to current treatment options." @default.
• W1965486534 created "2016-06-24" @default.
• W1965486534 creator A5048652296 @default.
• W1965486534 creator A5075800477 @default.
• W1965486534 date "2000-12-01" @default.
• W1965486534 modified "2023-10-18" @default.
• W1965486534 title "Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use" @default.
• W1965486534 cites W1732466172 @default.
• W1965486534 cites W1774580137 @default.
• W1965486534 cites W1967322264 @default.
• W1965486534 cites W1974093283 @default.
• W1965486534 cites W1976755012 @default.
• W1965486534 cites W1979178447 @default.
• W1965486534 cites W1986901191 @default.
• W1965486534 cites W1989869913 @default.
• W1965486534 cites W1992701784 @default.
• W1965486534 cites W2000174965 @default.
• W1965486534 cites W2004891879 @default.
• W1965486534 cites W2005790595 @default.
• W1965486534 cites W2006064798 @default.
• W1965486534 cites W2011738314 @default.
• W1965486534 cites W2021868794 @default.
• W1965486534 cites W2022517823 @default.
• W1965486534 cites W2039643007 @default.
• W1965486534 cites W2039687483 @default.
• W1965486534 cites W2045803772 @default.
• W1965486534 cites W2050771152 @default.
• W1965486534 cites W2059036925 @default.
• W1965486534 cites W2064017079 @default.
• W1965486534 cites W2065847144 @default.
• W1965486534 cites W2072923583 @default.
• W1965486534 cites W2074838078 @default.
• W1965486534 cites W2078784493 @default.
• W1965486534 cites W2079535194 @default.
• W1965486534 cites W2080109885 @default.
• W1965486534 cites W2087388267 @default.
• W1965486534 cites W2098517987 @default.
• W1965486534 cites W2104489235 @default.
• W1965486534 cites W2108104758 @default.
• W1965486534 cites W2157944766 @default.
• W1965486534 cites W2165320190 @default.
• W1965486534 cites W2322086287 @default.
• W1965486534 cites W2327247386 @default.
• W1965486534 doi "https://doi.org/10.1006/ebeh.2000.0126" @default.
• W1965486534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12737829" @default.
• W1965486534 hasPublicationYear "2000" @default.
• W1965486534 type Work @default.
• W1965486534 sameAs 1965486534 @default.
• W1965486534 citedByCount "56" @default.
• W1965486534 countsByYear W19654865342012 @default.
• W1965486534 countsByYear W19654865342013 @default.
• W1965486534 countsByYear W19654865342014 @default.
• W1965486534 countsByYear W19654865342015 @default.
• W1965486534 countsByYear W19654865342016 @default.
• W1965486534 countsByYear W19654865342017 @default.
• W1965486534 countsByYear W19654865342019 @default.
• W1965486534 countsByYear W19654865342020 @default.
• W1965486534 countsByYear W19654865342021 @default.
• W1965486534 countsByYear W19654865342022 @default.
• W1965486534 crossrefType "journal-article" @default.
• W1965486534 hasAuthorship W1965486534A5048652296 @default.
• W1965486534 hasAuthorship W1965486534A5075800477 @default.
• W1965486534 hasConcept C112705442 @default.
• W1965486534 hasConcept C118552586 @default.
• W1965486534 hasConcept C126322002 @default.
• W1965486534 hasConcept C197934379 @default.
• W1965486534 hasConcept C2777803345 @default.
• W1965486534 hasConcept C2778186239 @default.
• W1965486534 hasConcept C2778375690 @default.
• W1965486534 hasConcept C2779253243 @default.
• W1965486534 hasConcept C2781176495 @default.
• W1965486534 hasConcept C2994127763 @default.
• W1965486534 hasConcept C3018162438 @default.
• W1965486534 hasConcept C42219234 @default.
• W1965486534 hasConcept C71924100 @default.
• W1965486534 hasConcept C98274493 @default.
• W1965486534 hasConceptScore W1965486534C112705442 @default.
• W1965486534 hasConceptScore W1965486534C118552586 @default.
• W1965486534 hasConceptScore W1965486534C126322002 @default.
• W1965486534 hasConceptScore W1965486534C197934379 @default.
• W1965486534 hasConceptScore W1965486534C2777803345 @default.
• W1965486534 hasConceptScore W1965486534C2778186239 @default.
• W1965486534 hasConceptScore W1965486534C2778375690 @default.
• W1965486534 hasConceptScore W1965486534C2779253243 @default.
• W1965486534 hasConceptScore W1965486534C2781176495 @default.
• W1965486534 hasConceptScore W1965486534C2994127763 @default.
• W1965486534 hasConceptScore W1965486534C3018162438 @default.
• W1965486534 hasConceptScore W1965486534C42219234 @default.
• W1965486534 hasConceptScore W1965486534C71924100 @default.
• W1965486534 hasConceptScore W1965486534C98274493 @default.
• W1965486534 hasIssue "6" @default.
• W1965486534 hasLocation W19654865341 @default.
• W1965486534 hasLocation W19654865342 @default.
• W1965486534 hasOpenAccess W1965486534 @default.
• W1965486534 hasPrimaryLocation W19654865341 @default.
• W1965486534 hasRelatedWork W1490515507 @default.
• W1965486534 hasRelatedWork W1965486534 @default.
• W1965486534 hasRelatedWork W2098517987 @default.

• next